FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Went Gregory T 		2. Issuer Name and Ticker or Trading Symbol

Adamas Pharmaceuticals Inc [ ADMS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      __ X __ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 750 		3. Date of Earliest Transaction (MM/DD/YYYY)

4/10/2015
(Street)

EMERYVILLE, CA 94608
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   4/10/2015     M    1000   A $1.875   11008   (1) D    
Common Stock   4/10/2015     S    900   D $18.0889   (2) 10108   (1) D    
Common Stock   4/10/2015     S    100   D $19.00   10008   (1) D    
Common Stock   4/10/2015     S    3077   D $18.1595   (3) 402903   (1) I   Gregory T Went & Marjorie S Went ttees Went Family Living Trust dtd 03/24/11  
Common Stock   4/10/2015     S    500   D $19.07   (4) 402403   (1) I   Gregory T Went & Marjorie S Went ttees Went Family Living Trust dtd 03/24/11  
Common Stock   4/14/2015     M    80   A $1.875   10088   (1) D    
Common Stock   4/14/2015     S    80   D $18.00   10008   (1) D    
Common Stock   4/14/2015     S    10000   A $1.875   20008   (1) D    
Common Stock   4/14/2015     S    100   D $18.00   402303   (1) I   Gregory T Went & Marjorie S Went ttees Went Family Living Trust dtd 03/24/11  
Common Stock                  6666   I   Gregory T Went Cust - Bridget Went Under CA Uniform Transfers to Minors Act  
Common Stock                  6666   I   Gregory T Went Cust - Cora Went Under CA Uniform Transfers to Minors Act  
Common Stock                  80000   I   Gregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO Bridget Elise Went  
Common Stock                  80000   I   Gregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO Cora Margaret Went  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   $1.875   4/10/2015     M         1000      (5) 9/12/2016   Common Stock   1000   $0.00   230080   D    
Stock Option (Right to Buy)   $1.875   4/14/2015     M         80      (5) 9/12/2016   Common Stock   80   $0.00   230000   D    
Stock Option (Right to Buy)   $1.875   4/14/2015     M         10000      (5) 9/12/2016   Common Stock   10000   $0.00   220000   D    

Explanation of Responses:
( 1)  The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
( 2)  This transaction was executed in multiple trades at prices ranging from $18.00 to $18.31. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
( 3)  This transaction was executed in multiple trades at prices ranging from $18.00 to $18.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
( 4)  This transaction was executed in multiple trades at prices ranging from $19.00 to $19.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
( 5)  This option is fully vested and exercisable.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Went Gregory T
C/O ADAMAS PHARMACEUTICALS, INC.
1900 POWELL ST., SUITE 750
EMERYVILLE, CA 94608 		X X Chief Executive Officer

Signatures
/s/Grace Shin, as Attorney-in-Fact 4/14/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Adamas Pharmaceuticals Charts.
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Adamas Pharmaceuticals Charts.